Combining the data from both cohorts for methylated SEPT9 DNA gave the following results: Under the high specificity criteria, 3 out of 34 (9%) healthy controls and 27 out of 94 polyp patients (29%) as well as 24 out of 33 (73%) CRC patients were classified as positive. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.